Pioglitazone hydrochloride

An SGK1 inhibitor (IC₅₀s = 62 and 103 nM for SGK1 and SGK2, respectively) that demonstrates greater than 30-fold selectivity for SGK1 over Akt and other related kinases inhibits the androgen-stimulated growth of human prostate carcinoma

An SGK1 inhibitor (IC₅₀s = 62 and 103 nM for SGK1 and SGK2, respectively) that demonstrates greater than 30-fold selectivity for SGK1 over Akt and other related kinases inhibits the androgen-stimulated growth of human prostate carcinoma

An SGK1 inhibitor (IC₅₀s = 62 and 103 nM for SGK1 and SGK2, respectively) that demonstrates greater than 30-fold selectivity for SGK1 over Akt and other related kinases inhibits the androgen-stimulated growth of human prostate carcinoma

Application GW9662 has been used as a peroxisome proliferator activated receptor &#947: (PPAR&#947:) antagonist in human pluripotent stem cells, in phenylephrine stimulated cardiomyocytes and to inhibit the protective effect of telmisartan

Application GW9662 has been used as a peroxisome proliferator activated receptor &#947: (PPAR&#947:) antagonist in human pluripotent stem cells, in phenylephrine stimulated cardiomyocytes and to inhibit the protective effect of telmisartan

H3B-6545 is an oral, selective estrogen receptor covalent antagonist ( SERCA ) for the research of metastatic ER-positive, HER2-negative breast cancerIn VitroH3B-6545 is a highly selective small molecule that potently antagonizes wild-type and

H3B-6545 is an oral, selective estrogen receptor covalent antagonist ( SERCA ) for the research of metastatic ER-positive, HER2-negative breast cancerIn VitroH3B-6545 is a highly selective small molecule that potently antagonizes wild-type and

H3B-6545 is an oral, selective estrogen receptor covalent antagonist ( SERCA ) for the research of metastatic ER-positive, HER2-negative breast cancerIn VitroH3B-6545 is a highly selective small molecule that potently antagonizes wild-type and

H3B-6545 is an oral, selective estrogen receptor covalent antagonist ( SERCA ) for the research of metastatic ER-positive, HER2-negative breast cancerIn VitroH3B-6545 is a highly selective small molecule that potently antagonizes wild-type and

H3B-6545 is an oral, selective estrogen receptor covalent antagonist ( SERCA ) for the research of metastatic ER-positive, HER2-negative breast cancerIn VitroH3B-6545 is a highly selective small molecule that potently antagonizes wild-type and

H3B-6545 hydrochloride is an oral, selective estrogen receptor covalent antagonist ( SERCA ) for the research of metastatic ER-positive, HER2-negative breast cancerIn VitroH3B-6545 is a highly selective small molecule that potently antagonizes

H3B-6545 hydrochloride is an oral, selective estrogen receptor covalent antagonist ( SERCA ) for the research of metastatic ER-positive, HER2-negative breast cancerIn VitroH3B-6545 is a highly selective small molecule that potently antagonizes